(IPI) Intrepid Potash - Overview
Stock: Potassium Fertilizer, Magnesium Sulfate, Salt, Brine, Road Deicer
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 55.7% |
| Relative Tail Risk | -14.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.66 |
| Alpha | 16.22 |
| Character TTM | |
|---|---|
| Beta | 0.875 |
| Beta Downside | 1.028 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.60% |
| CAGR/Max DD | 0.00 |
Description: IPI Intrepid Potash December 27, 2025
Intrepid Potash Inc. (NYSE: IPI) produces and markets potassium-based fertilizers, magnesium and sulfur products, industrial salts, and water solutions through three operating segments: Potash, Trio (a blended fertilizer of potassium, sulfate, and magnesium), and Oilfield Solutions.
Key product lines include muriate of potash (used in crop nutrition, animal feed, and drilling fluids), specialty “Trio” granules, sodium chloride for de-icing and industrial use, magnesium chloride for road treatment, and brine solutions that support oil-field workovers and completions. The firm was founded in 2000 and is headquartered in Denver, Colorado.
Recent operational data (Q2 2024) show ≈ 2.2 million short tons of potash shipped, a 7 % YoY increase driven by higher global fertilizer demand and elevated crop-price expectations. The company’s gross margin expanded to 31 % as potash spot prices rose to $570/short ton, reflecting tighter supply from major producers. A sector-wide driver is the USDA’s projected 4 % rise in U.S. corn acreage, which underpins demand for potassium-rich fertilizers.
Assuming current commodity price trends persist, IPI’s earnings-before-interest-taxes-depreciation-amortization (EBITDA) could exceed $200 million for FY 2025; however, price volatility and geopolitical supply constraints introduce material uncertainty.
For a deeper dive into IPI’s valuation metrics, see the ValueRay analyst page.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -195.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.77 > 1.0 |
| NWC/Revenue: 64.43% < 20% (prev 57.55%; Δ 6.89% < -1%) |
| CFO/TA 0.09 > 3% & CFO 54.4m > Net Income -195.4m |
| Net Debt (-73.5m) to EBITDA (38.5m): -1.91 < 3 |
| Current Ratio: 5.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (13.2m) vs 12m ago 2.18% < -2% |
| Gross Margin: 16.57% > 18% (prev 0.10%; Δ 1646 % > 0.5%) |
| Asset Turnover: 39.11% > 50% (prev 31.70%; Δ 7.42% > 0%) |
| Interest Coverage Ratio: -7.63 > 6 (EBITDA TTM 38.5m / Interest Expense TTM 319.0k) |
Altman Z'' -0.30
| A: 0.29 (Total Current Assets 221.5m - Total Current Liabilities 42.2m) / Total Assets 616.5m |
| B: -0.26 (Retained Earnings -160.4m / Total Assets 616.5m) |
| C: -0.00 (EBIT TTM -2.43m / Avg Total Assets 711.4m) |
| D: -1.28 (Book Value of Equity -160.4m / Total Liabilities 125.8m) |
| Altman-Z'' Score: -0.30 = B |
Beneish M -4.00
| DSRI: 0.74 (Receivables 28.2m/34.9m, Revenue 278.3m/255.6m) |
| GMI: 0.62 (GM 16.57% / 10.33%) |
| AQI: 0.30 (AQ_t 0.10 / AQ_t-1 0.32) |
| SGI: 1.09 (Revenue 278.3m / 255.6m) |
| TATA: -0.41 (NI -195.4m - CFO 54.4m) / TA 616.5m) |
| Beneish M-Score: -4.34 (Cap -4..+1) = AAA |
What is the price of IPI shares?
Over the past week, the price has changed by +0.12%, over one month by +15.33%, over three months by +37.34% and over the past year by +28.29%.
Is IPI a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 2
What are the forecasts/targets for the IPI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24 | -27% |
| Analysts Target Price | 24 | -27% |
| ValueRay Target Price | 36.1 | 9.9% |
IPI Fundamental Data Overview February 03, 2026
P/S = 1.9797
P/B = 0.9207
P/EG = 0.34
Revenue TTM = 278.3m USD
EBIT TTM = -2.43m USD
EBITDA TTM = 38.5m USD
Long Term Debt = 1.92m USD (from longTermDebtTotal, last quarter)
Short Term Debt = 1.63m USD (from shortTermDebt, last fiscal year)
Debt = 3.71m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -73.5m USD (from netDebt column, last quarter)
Enterprise Value = 367.4m USD (440.9m + Debt 3.71m - CCE 77.2m)
Interest Coverage Ratio = -7.63 (Ebit TTM -2.43m / Interest Expense TTM 319.0k)
EV/FCF = 13.15x (Enterprise Value 367.4m / FCF TTM 28.0m)
FCF Yield = 7.61% (FCF TTM 28.0m / Enterprise Value 367.4m)
FCF Margin = 10.05% (FCF TTM 28.0m / Revenue TTM 278.3m)
Net Margin = -70.24% (Net Income TTM -195.4m / Revenue TTM 278.3m)
Gross Margin = 16.57% ((Revenue TTM 278.3m - Cost of Revenue TTM 232.2m) / Revenue TTM)
Gross Margin QoQ = 18.63% (prev 19.99%)
Tobins Q-Ratio = 0.60 (Enterprise Value 367.4m / Total Assets 616.5m)
Interest Expense / Debt = 0.97% (Interest Expense 36.0k / Debt 3.71m)
Taxrate = 6.59% (264.0k / 4.01m)
NOPAT = -2.27m (EBIT -2.43m * (1 - 6.59%)) [loss with tax shield]
Current Ratio = 5.24 (Total Current Assets 221.5m / Total Current Liabilities 42.2m)
Debt / Equity = 0.01 (Debt 3.71m / totalStockholderEquity, last quarter 490.7m)
Debt / EBITDA = -1.91 (Net Debt -73.5m / EBITDA 38.5m)
Debt / FCF = -2.63 (Net Debt -73.5m / FCF TTM 28.0m)
Total Stockholder Equity = 482.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.47% (Net Income -195.4m / Total Assets 616.5m)
RoE = -40.54% (Net Income TTM -195.4m / Total Stockholder Equity 482.1m)
RoCE = -0.50% (EBIT -2.43m / Capital Employed (Equity 482.1m + L.T.Debt 1.92m))
RoIC = -0.47% (negative operating profit) (NOPAT -2.27m / Invested Capital 482.1m)
WACC = 9.07% (E(440.9m)/V(444.7m) * Re(9.14%) + D(3.71m)/V(444.7m) * Rd(0.97%) * (1-Tc(0.07)))
Discount Rate = 9.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.54%
[DCF Debug] Terminal Value 65.52% ; FCFF base≈28.9m ; Y1≈19.0m ; Y5≈8.66m
Fair Price DCF = 16.11 (EV 142.8m - Net Debt -73.5m = Equity 216.3m / Shares 13.4m; r=9.07% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -64.02 | EPS CAGR: -35.26% | SUE: -1.10 | # QB: 0
Revenue Correlation: -45.49 | Revenue CAGR: -7.68% | SUE: 0.32 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.60 | Chg30d=+0.269 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.61 | Chg30d=+0.688 | Revisions Net=+2 | Growth EPS=-46.8% | Growth Revenue=-6.2%